Clinical Trial Update: A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase II neoadjuvant trial evaluating trastuzumab plus docetaxel and non-pegylated liposomal doxorubicin, with optional …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOCETAXEL (DOCETAXEL)
• Non-pegylated liposomal doxorubicin (doxorubicin liposome)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Austrian Breast & Colorectal Cancer Study Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED